This Article Full Text Full Text (PDF) An erratum has been published eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Related articles in The Oncologist Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miles, D. Articles by Seidman, A. D. Search for Related Content PubMed PubMed Citation Articles by Miles, D. Articles by Seidman, A. D.

Combination Versus Sequential Single-Agent Therapy in Metastatic Breast Cancer

^a Guy’s and St. Thomas’ Hospital, London, UK; ^b University Hospital, Frankfurt, Germany; ^c Memorial Sloan-Kettering Cancer Center and Cornell University Medical College, New York, New York, USA

David Miles, M.D., ICRF Breast Cancer Biology Unit, Guy’s and St. Thomas’ Hospital, Third Floor, Thomas Guy House, London, UK. Telephone: 44-0207-955-4542; Fax: 44-0207-955-2027; e-mail: d.miles{at}icrf.icnet.uk

The optimal treatment approach in metastatic breast cancer is controversial. Until recently, the arguments for administering antitumor agents sequentially in the metastatic setting have traditionally outweighed those for administering agents in combination. Older, often empirically designed drug combinations were no more effective and often more toxic than monotherapy, compromising quality of life for little or no clinical benefit. However, more recent studies show that combination and sequential therapy both have their place in the treatment of metastatic breast cancer, with the heterogeneity of breast cancer demanding flexibility in approach. Newer drug combinations, such as paclitaxel/trastuzumab or capecitabine/docetaxel, show survival advantages over single-agent therapy and have manageable safety profiles. Such combination treatments may be preferable to sequential therapy for patients requiring urgent reduction in their tumor burden. Sequential therapy allows the optimal delivery of single-drug therapy and potentially reduces the risk of toxicity, which may improve quality of life. Sequential therapy may be especially appropriate in frail or elderly patients, who may be unable to tolerate the toxicity of combination therapy, or in patients with slowly growing tumors. This article expands on these issues by reviewing trials comparing combination regimens with sequential approaches.

Key Words. Capecitabine • Taxanes • Breast cancer • Docetaxel • Sequential • Combination

Related articles in The Oncologist:

Combination Versus Sequential Single-Agent Therapy in Metastatic Breast Cancer

David Miles, Gunter von Minckwitz, and Andrew D. Seidman
The Oncologist 2003 8: 124. [Full Text]  

This article has been cited by other articles:

				D. Crivellari, M. Aapro, R. Leonard, G. von Minckwitz, E. Brain, A. Goldhirsch, A. Veronesi, and H. Muss Breast Cancer in the Elderly J. Clin. Oncol., May 10, 2007; 25(14): 1882 - 1890. [Abstract] [Full Text] [PDF]

				M. Bontenbal, G.-J. Creemers, H. J. Braun, A. C. de Boer, J. Th. Janssen, R. B. Leys, J. B. Ruit, S. H. Goey, P. C. van der Velden, L. G. Kerkhofs, et al. Phase II to III Study Comparing Doxorubicin and Docetaxel With Fluorouracil, Doxorubicin, and Cyclophosphamide As First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre J. Clin. Oncol., October 1, 2005; 23(28): 7081 - 7088. [Abstract] [Full Text] [PDF]

				J. O'Shaughnessy Extending Survival with Chemotherapy in Metastatic Breast Cancer Oncologist, October 1, 2005; 10(suppl_3): 20 - 29. [Abstract] [Full Text] [PDF]

				C. L. Vogel and E. Tan-Chiu Trastuzumab Plus Chemotherapy: Convincing Survival Benefit or Not? J. Clin. Oncol., July 1, 2005; 23(19): 4247 - 4250. [Full Text] [PDF]

				A. Hamilton and G. Hortobagyi Chemotherapy: What Progress in the Last 5 Years? J. Clin. Oncol., March 10, 2005; 23(8): 1760 - 1775. [Full Text] [PDF]

				E. Alba, M. Martin, M. Ramos, E. Adrover, A. Balil, C. Jara, A. Barnadas, A. Fernandez-Aramburo, P. Sanchez-Rovira, M. Amenedo, et al. Multicenter Randomized Trial Comparing Sequential With Concomitant Administration of Doxorubicin and Docetaxel As First-Line Treatment of Metastatic Breast Cancer: A Spanish Breast Cancer Research Group (GEICAM-9903) Phase III Study J. Clin. Oncol., July 1, 2004; 22(13): 2587 - 2593. [Abstract] [Full Text] [PDF]